MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
3. Government ... Funders, Regulators, Policy Makers, Conveners
*Government: International
Europe
*Europe: Regions
*Western Europe
Ireland
*Industry: Ireland
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)*
Organization & Developments: Jazz Pharmaceuticals
Parents
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)*
Children
*A sleep disorder, narcolepsy causes extreme drowsiness every three or four hours during the day, episodes that typically last about 15 minutes.
*Company developed Xyrem, a prescription medication approved to treat cataplexy associated with narcolepsy and Excessive Daytime Sleepiness associated with narcolepsy.
*The company also makes Luvox CR, approved to treat social anxiety and obsessive-compulsive disorders.
*The drug treatment costs at least $30,000 a year, but is covered by insurance.
2013: Green Mountain, Michael Kors Lead IBD 50's 6 Earnings This Week (2013)
2016: Jazz Pharma: No Longer Singing The Blues With Multiple 2016 Catalysts - Jazz Pharmaceuticals, Inc. (NASDAQ:JAZZ)
2017: ImmunoGen inks ADC development deal with Jazz Pharma valued at least $175M; shares ahead 11% premarket - ImmunoGen, Inc. (NASDAQ:IMGN)
2020: Jazz Pharma Gets FDA Nod for New Drug to Treat Narcolepsy Symptoms
2020: Jazz Pharma Gets Quick FDA OK for New Small Cell Lung Cancer Drug
2021: Jazz Pharmaceuticals: Narcolepsy Franchise Concerns Weigh On Investor Sentiment
2022: Avadel And Jazz: The Oxybate Wars - Duking It Out_ seekingalpha.com
2022: Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFNα INDUKINE™ Molecule werewolf therapeutics
2022: Jazz Pharmaceuticals plc 2022 Q3 - Results - Earnings Call Presentation_ seekingalpha.com
2022: Jazz Pharmaceuticals: Q3 Results, Pipeline Cleanup, And An Unhappy FTC_ seekingalpha.com
2022: Jazz Pharmaceuticals' Deal With Zymeworks Offers Good Reward-Risk Ratio_ seekingalpha.com
2022: Zymeworks wanted a Big Pharma partner for its bispecific. Jazz Pharmaceuticals said OK
2023: Jazz Pharmaceuticals: State Of Play Ahead Of Q1 Earnings_ seekingalpha.com
2023: Jiving with Jazz after $325M opt-in, Zymeworks links HER2 bispecific to 84% survival after 18 months
2024: Is Jazz Pharmaceuticals plc (JAZZ) the Most Promising Biotech Stock According to Hedge Funds?
2024: Jazz Pharmaceuticals plc 2023 Q4 - Results - Earnings Call Presentation
2024: Jazz Pharmaceuticals: Cheap But Complicated_ seekingalpha.com
2024: Jazz Pharmaceuticals: Should Sing A Better Tune In 2025
2024: Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off_ seekingalpha
2024: Jazz Pharmaceuticals: Unexpected Wins Improve The Long-Term Outlook
2024: Jazz Pharmaceuticals: Unexpected Wins Improve The Long-Term Outlook
2024: Jazz Pharmaceuticals: Zanidatamab Is A Potential Growth Catalyst
2024: Jazz Touts Survival Benefit for First-Line Maintenance Therapy in SCLC
2024: Jazz's almost-withdrawn lung cancer drug Zepzelca extends life on top of Roche's Tecentriq
2024: Updated View On Jazz Pharmaceuticals' 2025 Goals
2025: Jazz Pharmaceuticals: I See Big Potential In This Stock As An Investor
2025: Jazz Pharmaceuticals: One Step Forward, One Back
2026: Jazz Pharmaceuticals' Re-Rating Story Has Legs
2026: Jazz Pharmaceuticals’ Record Revenue And Cancer Data Raise Durability Question
Jumps
*Key People: Jazz Pharmaceuticals
Finance & Acquisitions: Jazz Pharmaceuticals